ArticleAdvances in therapyPublished
Indirect Comparison of Nipocalimab Versus Efgartigimod and Rozanolixizumab in the Treatment of Generalized Myasthenia Gravis
Regional connection
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
- Institution
- Johnson & Johnson
- County
- Montgomery County
Publication record
- Type
- Article
- Venue
- Advances in therapy
- Published
- Topic
- Clinical care
- Subject terms
- Humans; Myasthenia Gravis; Receptors, Fc; Histocompatibility Antigens Class I; Treatment Outcome; Activities of Daily Living; Antibodies, Monoclonal, Humanized; Indirect Treatment Comparison; Generalized Myasthenia Gravis; Matching-adjusted Indirect Comparison; Rozanolixizumab; Efgartigimod
- PubMed ID
- 41817915
- PubMed Central ID
- PMC13156109
- Open access
- Yes, open
- Added to directory
- Source checked